DiagnoCure appoints Richard Bordeleau as Senior Advisor to the board
20 August 2013 - 9:30PM
OTC Markets
DiagnoCure appoints Richard Bordeleau as Senior Advisor to the
board
#ReleaseContent TABLE
{
BORDER-COLLAPSE: collapse
}
TR.cnwUnderlinedCell TD
{
BORDER-BOTTOM: #000000 1px solid
}
TR.cnwDoubleUnderlinedCell TD
{
BORDER-BOTTOM: #000000 3px double
}
TR.cnwBoldUnderlinedCell TD
{
BORDER-BOTTOM: #000000 3px solid
}
TD.cnwUnderlinedCell
{
BORDER-BOTTOM: #000000 1px solid
}
TD.cnwDoubleUnderlinedCell
{
BORDER-BOTTOM: #000000 3px double
}
TD.cnwBoldUnderlinedCell
{
BORDER-BOTTOM: #000000 3px solid
}
#ReleaseContent TABLE.cnwBorderedTable TD
{
BORDER-RIGHT: black 1px solid;
PADDING-RIGHT: 2px;
BORDER-TOP: black 1px solid;
PADDING-LEFT: 2px;
PADDING-BOTTOM: 2px;
BORDER-LEFT: black 1px solid;
PADDING-TOP: 2px;
BORDER-BOTTOM: black 1px solid;
BORDER-COLLAPSE: collapse
}
#ReleaseContent TABLE TD
{
PADDING-RIGHT: 2px;
PADDING-LEFT: 2px;
PADDING-BOTTOM: 2px;
PADDING-TOP: 2px
}
DiagnoCure appoints Richard Bordeleau as Senior Advisor to the
board
PR Newswire
QUEBEC CITY, Aug. 20, 2013
Appointment Targeting Next Steps to Increasing Shareholder
Value
QUEBEC CITY, Aug. 20, 2013
/PRNewswire/ - DiagnoCure, Inc. (TSX: CUR)
(OTCQX: DGCRF), a life sciences company developing and
commercializing
high?value cancer diagnostic tests, today announced the appointment
of
Mr. Richard Bordeleau as Senior
Advisor to the Company effective
September 1, 2013. Mr. Bordeleau will
act as an executive in residence
and report directly to DiagnoCure's board of directors. In
collaboration with Company management, Mr. Bordeleau's initial
mandate
will be to identify and implement short term actions aimed at
increasing shareholder value, and also to evaluate mid to long
term
scenarios optimizing corporate value.
Mr. Bordeleau joins DiagnoCure, following a highly successful
international career in the life sciences industry. During his term
as
President of Atrium Innovations from 2000 to 2007, the company
experienced sustainable double-digit organic growth through
direct
sales combined with international license and distribution
agreements,
augmented by multiple accretive acquisitions in North America and
Europe. Mr. Bordeleau also more
recently contributed to the growth of
BioCad Medical, positioning the company as a leader in CADCAM
dentistry. BioCad Medical was purchased by Nobel Biocare 18
months
after he joined the company. Mr. Bordeleau currently manages
investments in start-up companies together with members of
Anges
Quebec, a network of business angels where he initiated investments
in
life sciences as responsible of the health and well-being
sector.
"We are extraordinarily pleased that Mr. Bordeleau will be joining
the
DiagnoCure team. His strong track record of growing companies
and
creating value for shareholders is a powerful testament to his
strength
in successfully negotiating and closing international licensing
and
distribution agreements, and implementing value-creating
acquisitions," said Dr. Yves
Fradet, Chairman of the Board.
"Reporting directly to the Board, Mr. Bordeleau's business acumen
will
complement the scientific strengths of DiagnoCure's management team
and
the clinical insight of our Chairman. The board has given
Richard
significant powers to act as executive in residence in the creation
of
both a long-term vision for success and a short-term improvement
of
shareholder value," added Dr. Vincent
Zurawski, DiagnoCure's Lead
Director.
About DiagnoCure
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation
that
develops and commercializes high value cancer diagnostic tests
that
increase clinician and patient confidence in making critical
treatment
decisions. In 2008, the Corporation launched a colorectal
cancer
staging test through its U.S. CLIA laboratory.
PrevistageTM GCC is currently available for licensing.
The Corporation has granted a
worldwide exclusive license on PCA3 to Gen?Probe, now a
wholly?owned
subsidiary of Hologic Inc., operating as Hologic Gen?Probe, for
the
development and commercialization of a prostate cancer test,
DiagnoCure's proprietary molecular biomarker. Hologic
Gen?Probe's
PROGENSA® PCA3 test is commercialized in Europe under CE mark and is
approved for commercialization in Canada and the
United States. For
more information, please visit www.diagnocure.com.
Forward?looking statements
This release contains forward?looking statements that involve known
and
unknown risks, uncertainties and assumptions that may cause
actual
results to differ materially from those expected. By their very
nature,
forward?looking statements are based on expectations and hypotheses
and
also involve risks and uncertainties, known and unknown, many of
which
are beyond DiagnoCure's control. As a result, investors are
cautioned
not to place undue reliance on these forward?looking statements.
The
forward-looking statements regarding the outcome of research
and
development projects, clinical studies and future revenues are
based on
management expectations. In addition, the reader is referred to
the
applicable general risks and uncertainties described in
DiagnoCure's
most recent Annual Information Form under the heading "Risk
Factors".
DiagnoCure undertakes no obligation to publicly update or revise
any
forward?looking statements contained herein unless required by
the
applicable securities laws and regulations.
SOURCE DiagnoCure inc.
Diagnocure (CE) (USOTC:DGCRF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnocure (CE) (USOTC:DGCRF)
Historical Stock Chart
From Jul 2023 to Jul 2024